特兰克萨姆酸用于抗胰岛素转化酶抑制剂诱导的血管发炎
Gaurav Nitin Pathak1, Thu Minh Truong2, Abhishek Chakraborty1
1Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
Clinical and experimental emergency medicine
|August 1, 2023
概括
特兰胺酸 (TXA) 可能有效地治疗血管素转化酶抑制剂诱导的血管瘤 (ACEI-IA). 这篇评论表明,TXA可以改善症状,并在紧急情况下预防输管.
科学领域:
- 药理学 药理学是指药理学的学科.
- 紧急医疗 紧急医疗
- 免疫学 免疫学 免疫学
背景情况:
- ангиотензин转化酶抑制剂 (ACEI) 可能导致血管 (ACEI-IA),这是一个罕见但严重的不良反应,影响约0.7%的用户.
- 目前,没有FDA批准的治疗方法存在于ACEI-IA,导致显著的患者风险和潜在的并发症,如气道阻塞.
- 布拉迪基宁的过度生产与ACEI-IA的病理生理学有关,这表明潜在的治疗点.
研究的目的:
- 审查关于特兰胺酸 (TXA) 用于治疗ACEI诱导的血管 (ACEI-IA) 的安全性和有效性的现有文献.
- 评估TXA在管理ACEI-IA方面的潜在作用,特别是在紧急情况下.
- 评估TXA是否可以缓解诸如输内管的需要等并发症.
主要方法:
- 在PubMed上对2003年1月至2023年1月期间发表的研究进行了系统的文献搜索.
- 纳入的研究重点是针对在患有ACEI诱导的血管瘤 (ACEI-IA) 患者中使用松酸 (TXA) 的研究.
- 七项研究符合审查的预定义纳入标准.
主要成果:
- 审查的研究表明,特兰胺酸 (TXA) 可能导致 ACEI-IA 患者的血管症状改善.
- 有证据表明,TXA可能可以在患有ACEI-IA.IA的患者中预防输管治疗的需要.
- TXA因其可用性,低成本和良好的安全性而闻名,使其成为应急管理的可行选择.
结论:
- 特兰胺酸 (TXA) 显示出作为ACEI诱导的血管瘤 (ACEI-IA) 的安全和有效治疗的希望.
- TXA可能有助于缓解症状,并预防与ACEI-IA相关的严重并发症,如输管.
- 它的可访问性和成本效益支持在ACEI-IA管理的紧急协议中考虑它.
相关概念视频
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
692
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
692
Antihypertensive Drugs: Direct Renin Inhibitors
684
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
684
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
Antihypertensive Drugs: Angiotensin II Receptor Blockers
780
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
780
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
565
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
565
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
201
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
201


